High-performance liquid chromatographic assay of plasma thalidomide: stabilization of specimens and determination of a tentative therapeutic range for chronic graft-versus-host disease.
Ann Clin Biochem
; 32 ( Pt 1): 79-83, 1995 Jan.
Article
em En
| MEDLINE
| ID: mdl-7762955
ABSTRACT
Thalidomide is now widely used to treat chronic graft-versus-host disease, but its use is associated with non-teratogenic side effects such as peripheral neuropathy. To examine the value of monitoring plasma concentrations of the drug in such patients, we have developed a high-performance liquid chromatographic (HPLC) assay. The method uses 0.5 mL plasma, is linear to 10 mg/L and had a detection limit of 0.2 mg/L. Thalidomide in plasma specimens was unstable at physiological pH but could be stabilized for several weeks by simple acidification. We describe a protocol for monitoring patients treated with thalidomide which permits convenient transportation and storage of specimens and report, provisionally, that plasma concentrations in the range 1-7 mg/L are therapeutically effective in chronic graft-versus-host disease without adverse side effects.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Manejo de Espécimes
/
Talidomida
/
Cromatografia Líquida de Alta Pressão
/
Doença Enxerto-Hospedeiro
/
Monitorização Fisiológica
Tipo de estudo:
Guideline
Limite:
Humans
/
Male
Idioma:
En
Revista:
Ann Clin Biochem
Ano de publicação:
1995
Tipo de documento:
Article
País de afiliação:
Reino Unido